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ABSTRACT 
Recently, disappearance of oligoclonal bands (OCB) from the CSF of a few natalizumab-treated patients with 
MS has been reported. This is interesting since CSF-restricted OCB are considered to persists in MS.  
Since lumbar punctures during natalizumab therapy are infrequent we pooled CSF data from fourteen MS 
centers to obtain a suitable patient cohort for furhter investigations about the suspected impact of 
natalizumab on CNS-restricted humoral immune activities.   
In a retrospective chart analysis CSF parameters of blood-CSF barrier integrity and intrathecal IgG production 
from 73 natalizumab-treated MS patients requiring a diagnostic puncture for exclusion of progressive 
multifocal leukoencephalopathy were compared with CSF data obtained earlier in the course of disease before 
natalizumab therapy.  
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Introduction     
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing- remitting multiple 
sclerosis (RRMS) and interferes with immune cell migration into the CNS by binding to the adhesion molecule 
very late activation antigen-4 (VLA-4).1 The result is a pronounced and sustained reduction of immune cell 
numbers in the CSF.2  
Less knowledge exists about natalizumab interfering with intrathecal humoral immune 
activities. Recently, disappearance of oligoclonal bands (OCB) during natalizumab therapy in 
4 out of 6 patients was reported from von Glehn et al.3 This is very interesting and 
substantiates the importance of investigating intrathecal antibody production in response to 
natalizumab treatment because, in contrast to other CNS diseases including neuromyelitis 
optica4, CSF-restricted OCB have been reported to persist in MS.5,6  
Since CSF data from patients during natalizumab therapy is scarce, we collected CSF data 
from several specialized MS centers to obtain an appropriate sample size for determining 
significant changes in CNS-restricted humoral immune activity attributable to natalizumab 
therapy.  
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Patients and methods 
Patients 
CSF parameters from 73 patients (mean age 37.0, range 17-65) with RRMS were collected retrospectively at 
fourteen German, Swiss, and Austrian hospitals. Lumbar punctures were performed (i) at first diagnosis of MS 
and/or other routine diagnostic purposes before natalizumab therapy, and ii) for diagnostic purposes after an 
average of 30 months (SD 17.9) on natalizumab therapy, in particular, to rule out progressive multifocal 
leukoencephalopathy (PML). In 7 patients (10%) presence of PML was confirmed by the detection of JC virus 
DNA by PCR. In 16 patients natalizumab therapy was terminated or paused leading to intervals of >8 weeks 
between the last natalizumab infusion and lumbar puncture.   
 
CSF parameters 
CSF data were obtained from MS centers whose laboratories participate at interlaboratory 
testing and/or are certified by the German Society of CSF Diagnostics and Clinical 
Neurochemistry (Deutsche Gesellschaft für Liquordiagnostik und klinische Neurochemie, 
DGLN). IgG and albumin concentrations of CSF and serum samples were measured by 
immunonephelometry and used to calculate the CSF/serum quotients for IgG and albumin 
(QIgG, QAlb). Blood-CSF barrier integrity was assessed by QAlb with the upper reference 
limit of the age-dependent QAlb calculated according to Reiber et al.7 Intrathecal IgG 
synthesis was quantified as the relative intrathecal IgG fraction (IgGIF) using the CSF/serum 
quotient diagrams according to Reiber6. Since quantitative data were not available in several 
cases IgGIF and QAlb were dichotomized into normal or pathologic for statistical analysis. 
Detection of OCB was performed by isoelectric focusing and presence or absence of OCB in 
the CSF but not in serum was evaluated qualitatively.  
 
Statistics 
McNemar's test was used to compare differences in CSF parameters from the two lumbar 
punctures. Person-Cloppers values were used to compute 95% confidence intervals (CI) for 
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the difference of proportions. A p-value less than 0.05 indicates a statistically significant 
difference. Computations were done using StatXact 6.0 (Cytel Software Corporation, 
Cambridge MA). 
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Results  
Due to the retrospective design of our study some CSF parameters, mainly of the first lumbar puncture, were 
not available. For statistical analysis only patients with data available from both lumbar punctures were 
included. Accordingly, comparative analysis of blood-CSF barrier integrity was performed from 42 patients and 
of IgGIF from 40 patients. Disappearance of OCB was evaluated from 73 patients. An overview of the results is 
given in the table. 
At the first lumbar puncture an increased QAlb was determined in 26% (11/42) and local IgG production 
(represented by IgGIF) was measured in 80% (32/40) of the patients. OCB were positive in 63 and unknown in 
10. These 10 patients were OCB positive at the 2nd lumbar puncture and therefore assumed to be positive at 
the time of the 1st lumbar puncture.  At the second lumbar puncture the frequency of blood-CSF barrier 
dysfunction was 17% (4/42) indicating little or no effects of natalizumab therapy on the blood-CSF barrier 
integrity (p=0.15). The frequency of IgGIF was only 55% (18/40) at the second measurement and significantly 
lower compared to the 80% at the first lumbar puncture (p<0.0001; observed difference: 35%, 95% CI for the 
difference: 22-50%). OCB had disappeared in 16% (12/73) of the patients (p<0.003; observed difference: 16%, 
95% CI for the difference: 9-27%) who were OCB positive at the first lumbar puncture. Very similar results were 
obtained upon excluding patients with confirmed PML and patients with an interval of more than 8 weeks 
between the last natalizumab infusion and lumbar puncture.  
Particularly interesting were 2 cases with disappeared OCB despite an interval of 5.5 and 6 months since the 
last natalizumab infusions and 1 patient with confirmed PML in whom OCB had disappeared during 
natalizumab therapy but had reappeared following plasma exchange (PLEX) therapy (personal communication 
M. Linnebank).  
Discussion 
Our results corroborate findings from a small study in 6 patients by von Glehn at al.3 and 
provide further evidence that natalizumab therapy has an effect on B cell activity and 
antibody production within the CNS. The pivotal question concerns the relevance of 
decreased intrathecal IgG synthesis and disappearance of OCB in response to natalizumab 
therapy. All the more so, as this effect apparently is specific to natalizumab since selective 
targeting of B cells by rituximab or arresting lymphocytes within lymph nodes by fingolimod 
were reported not to affect intrathecal IgG synthesis or OCB.8-10 Absence of immunologic 
crosstalk due to natalizumab-mediated blockade of VLA-4, interference with plasma cell 
attachment to their CNS niches, or unknown direct effects of natalizumab on CNS B-lineage 
cells are all possible mechanisms though speculative.  
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Both studies – the one of von Glehn at al.3 and ours - included one case of PML in whom OCB 
had disappeared at the time of PML diagnosis but became positive again after plasma 
exchange (PLEX) therapy which indicates a possible involvement of immune cell interactions 
in the maintenance of intrathecal IgG production. Apparently, re-availability of immune cells 
facilitated a re-boost of intrathecal IgG synthesis. Contrary, OCB still were disappeared in 
two of our patients despite an interval of about 6 months between the diagnostic lumbar 
puncture and the last natalizumab infusion. Natalizumab therapy possibly also effects a 
prolonged impact on intrathecal antibody production, similar to or maybe because of the 
sustained decrease in immune cell availability as reported by Stueve et al2.  
The retrospective design with laboratory results from different centers and the bias of a diagnostic lumbar 
puncture mainly performed to rule out PML certainly are limitations of our study. On the other hand, data were 
provided from specialized MS centers with certified laboratories/laboratories participating at interlaboratory 
testing and we achieved a suitable patient cohort for statistical analysis though lumbar punctures from patients 
under natalizumab therapy are infrequent.  
In conclusion, our larger cohort confirms that natalizumab therapy affects B cell-derived activity within the 
CNS. However, a conclusion on disease- or treatment-relevance of this finding cannot be drawn at this point. 
Clarification of the underlying mechanisms and a prospective study including patients with a stable disease 
course could provide further knowledge on efficacy and mode of action of natalizumab therapy. 
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Table. Summarized CSF parameters from patients with available data of both lumbar punctures (before and 
during  natalizumab therapy) and estimates on significance of observed changes 
 1st puncture 2nd puncture McNemar Test 
 n [%] n [%] n p-value % difference 
    (95% CI for difference) 
Evidence of intrathecal IgG synthesis     
Intrathecal synthesized fraction determined by Reibergram    
Normal   8 [20%] 22 [45%] 40 p<0.0001 35% (22-50%) 
                 Pathologic 32 [80%] 18 [55%]    
OCB determined by isoelectric focussing     
Negative   0 [0%] 12 [16%] 73 p<0.003 16% (9-27%) 
Positive 73 [100%]* 61 [84%]    
 
Blood-CSF barrier function (QAlb)     
Normal  31 [74%] 35 [83%] 42 p=0.15 9% (-24-4%) 
        Pathologic 11 [26%] 7 [17%]    
Abbreviations: CI, confidential interval; CSF, cerebrospinal fluid; IgG, immunoglobulin G; n, number of 
patients; QAlb, albumin quotient; OCB, oligoclonal bands 
*of 10 patients OCB were not stated and assumed positive.  
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